MaxCyte Inc. (NASDAQ:MXCT) trading with a subtraction of -$0.44 to $10.27 on Friday, a downside of -4.12 percent. An average of 652,326 shares of common stock have been traded in the last five days. There was a fall of -$1.45 in the past week. The last 20 days have seen an average of 774,317 shares traded.
MXCT stock has decreased by -36.96% in the last month. The company shares reached their 1-month lowest point of $9.45 on 10/08/21. Shares of the company touched a low of $5.85 and a high of $17.44 in 52 weeks. In spite of this, the price is down -41.12% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
MaxCyte Inc. (MXCT) has a trailing price-to-earnings (P/E) ratio of 26.50 for the broader industry and 31.99 for the sector. This means investors are optimistic about the stock’s future prospects.
On the profitability front, the trailing 12-month gross margin 5-year average of 89.2%. MaxCyte Inc.’s EBITDA margin for the year ending June 29 is -37.94%. Its gross profit as reported stood at $23.4 million compared to revenue of $26.17 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. MaxCyte Inc.’s return on assets was -36.9% over the last five years. For the broader industry, ROE averaged -2.89 over the past year.
The analyst consensus anticipated MaxCyte Inc.’s latest quarter earnings to come in at -$0.06 per share, but it turned out to be -$0.05, a 16.70% surprise. For the quarter, EBITDA amounted to -$4.1 million. Shareholders own equity worth $100.41 million.
From a technical analysis perspective, let’s take a brief look at MaxCyte Inc. (MXCT) price momentum. RSI 9-day as of the close on 07 October was 12.93%, suggesting the stock is oversold, with historical volatility in this time frame at 34.69%.
As of today, MXCT’s price is $10.72 -12.72% or -$1.45 from its 5-day moving average. MXCT is currently trading -35.18% lower than its 20-day SMA.
The stochastic %K and %D were 6.69% and 8.15%, respectively, and the average true range (ATR) was 0.87. With the 14-day stochastic at 9.01% and the average true range at 0.90, the RSI (14) stands at 20.14%. The stock has reached -0.95 on the 9-day MACD Oscillator while the 14-day reading was at -1.85.
William Blair launched coverage on MaxCyte Inc. (NASDAQ: MXCT) in its analyst report released on August 24, 2021. The firm assigned the stock a an Outperform rating.The consensus rating for MaxCyte Inc. (MXCT) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell MXCT, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is MXCT’s price target for the next 12 months?
Analysts predict a range of price targets between $17.18 and $22.00, with a median target of $18.00. Taking a look at these predictions, the average price target given by analysts for MaxCyte Inc. (MXCT) stock is $18.73.